within Pharmacolibrary.Drugs.R_RespiratorySystem.R07A_OtherRespiratorySystemProducts.R07AX31_IvacaftorAndTezacaftor;

model IvacaftorAndTezacaftor
  extends Pharmacolibrary.Drugs.ATC.R.R07AX31;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R07AX31</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ivacaftor and tezacaftor are combined as a fixed-dose oral therapy indicated for the treatment of cystic fibrosis in patients with specific CFTR gene mutations. Ivacaftor is a CFTR potentiator, increasing chloride transport, while tezacaftor is a CFTR corrector that improves processing and trafficking of the protein to the cell surface. The combination is approved for use in several countries, including the US and EU.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic analysis in healthy adult volunteers; oral administration as fixed combination. Typical population: adults aged 18-50 years, both sexes.</p><h4>References</h4><ol><li><p>Flume, PA, et al., &amp; Wainwright, CE (2021). Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. <i>The Lancet. Respiratory medicine</i> 9(7) 733â€“746. DOI:<a href=&quot;https://doi.org/10.1016/S2213-2600(20)30510-5&quot;>10.1016/S2213-2600(20)30510-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33581080/&quot;>https://pubmed.ncbi.nlm.nih.gov/33581080</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end IvacaftorAndTezacaftor;
